First Canadian patient dosed in cell therapy trial for corneal edema

ByAlex Young

Fact checked byEamon N. Dreisbach

Key takeaways:

The study will evaluate three different doses of neltependocel.
Approximately 100 patients will be included in the study.

The first Canadian patient has been dosed in a phase 1/2 trial of a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.

The drug, AURN001 (Aurion Biotech), is a combination cell therapy that consists of neltependocel and Y-27632, according to a press release. AURN001 is intended to be administered to the eye as a one-time intracameral injection.

Close up eye — The first Canadian patient has been dosed in a phase 1/2 trial of a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.
*Image: Adobe Stock*

Approximately 100 patients will be included in the ABA-1/CLARA study, which is designed to examine three different doses of neltependocel used in combination with Y-27632, according to the release.

“We know that corneal dystrophies such as Fuchs’ affect about 4% of eyes over the age of 40,” Aurion CEO Greg Kunst told Healio in an email. “We hope that the outcomes from our ABA-1/CLARA trial will contribute meaningful insights to the treatment of this sight-threatening condition.”

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Disclosures: Kunst reports being an employee of Aurion Biotech.

Read more

First Canadian patient dosed in cell therapy trial for corneal edema

Key takeaways:

Related Content